http://www.fpnotebook.com/
Chronic Renal Failure
Aka: Chronic Renal Failure, End Stage Renal Disease, Chronic Kidney Disease, Chronic Renal Insufficiency, ESRD, CRF
- See Also
- Chronic Kidney Disease related Bone Disease (Renal Osteodystrophy)
- Proteinuria
- Drug Dosing in Chronic Kidney Disease
- Nephrotoxic Drugs
- Prevention of Kidney Disease Progression
- Intravenous Contrast Related Acute Renal Failure
- Gadolinium-Associated Nephrogenic Systemic Fibrosis (Nephrogenic Fibrosing Dermopathy)
- Epidemiology: Prevalence
- Chronic Kidney Disease
- Adults in U.S.: 20 million (11% of the adult population)
- End Stage Renal Diseases
- Actual 2002: 435,000 in U.S.
- Estimated 2010: 650,000 in U.S.
- Causes: Percentage is that of conditions responsible for ESRD
- Diabetes Mellitus (37%)
- See Diabetic Nephropathy
- Glycemic control is critical to slow progression
- Type I Diabetes Mellitus (represents 5% of ESRD patients)
- Progresses to ESRD in 40% of patients
- Type II Diabetes Mellitus (represents 32% of ESRD patients)
- Progresses to ESRD in 20% of patients
- Type II Diabetes is 10 times as common as Type
- Hypertension (25%)
- Glomerulonephritis and other glomerular diseases (21%)
- Includes Vasculitis (e.g. Systemic Lupus Erythematosus)
- Polycystic Kidney Disease (7%)
- Tubulointerstitial disease (4%)
- Urologic disease
- Chronic Urinary Tract Infections (Pyelonephritis)
- Nephrolithiasis (obstruction)
- Medication-induced Nephrotoxicity (nephrotoxins)
- See Intravenous Contrast Related Acute Renal Failure
- See Risk Score for Prediction of Contrast-Induced Nephropathy After Percutaneous Coronary Intervention
- Risk Factors
- Diabetes Mellitus (leading cause)
- Autoimmune Conditions
- Chemical exposures (Lead, Cadmium, Arsenic, Mercury, Uranium)
- Nephrotoxin exposure (e.g. Intravenous Contrast Related Acute Renal Failure)
- Family History of Chronic Kidney Disease
- Hypertension
- Low birth weight
- Lower Urinary Tract Obstruction
- Cancer
- Nephrolithiasis
- Advanced age
- Acute Kidney Injury in past
- Decreased Renal Mass
- Serious systemic infection (e.g. Sepsis)
- Recurrent Urinary Tract Infections
- Minority status (blacks, native american, asian, pacific islander)
- History
- Recent infections
- Poststreptococcal Glomerulonephritis
- STD risk factors
- HIV Infection
- Hepatitis B Infection
- Hepatitis C Infection
- Arthritis or dermatitis
- Systemic Lupus Erythematosus
- Cryoglobulinemia
- Urinary symptoms
- Urinary Tract Infection
- Nephrolithiasis
- Urinary outflow obstruction
- PMH
- Diabetes Mellitus
- Present for 5-10 years: Microalbuminuria, Pre-Hypertension
- Present for 10-15 years: Albuminuria, Retinopathy, Hypertension
- Hypertension
- Severe Hypertension
- End-organ effects
- Family History
- Polycystic Kidney Disease
- Alport Syndrome (X-linked)
- Exam
- Vital Signs
- Hypertension
- Increased Body Mass Index
- Eye Exam
- Hypertensive retinopathy (A-V Nicking)
- Diabetic Retinopathy
- Cardiovascular Exam
- Congestive Heart Failure
- Ventricular Hypertrophy
- Carotid Bruit
- Decreased peripheral pulses
- Abdominal Exam
- Renal artery bruit
- Flank pain
- Bladder distention
- Symptoms: Stage 4-5
- Fatigue (75% of patients)
- Pruritus (75% of patients)
- Weakness
- Headaches
- Anorexia
- Nausea
- Vomiting
- Polyuria
- Nocturia
- Pain
- Musculoskeletal pain
- Dialysis associated pain
- Peripheral Neuropathy
- Peripheral Vascular Disease related pain
- Signs
- See Edema in Chronic Renal Failure
- Hypertension
- Congestive Heart Failure
- Proteinuria
- Pericarditis
- Criteria: Chronic Kidney Disease
- Kidney damage for >3 months or
- GFR < 60 ml/min/1.73 m2 (based on two GFR calculations 3 months or more apart)
- Men: Serum Creatinine >1.5 mg/dl
- Women: Serum Creatinine >1.3 mg/dl
- Significant Proteinuria for >3 months
- Urine Albumin >300 mg/24 hours or
- Urine Albumin to Creatinine Ratio 200 mg/gram
- Stages: NKF Classification System
- Stage 1: GFR >90 ml/min despite Kidney damage
- Microalbuminuria present
- Stage 2: Mild reduction (GFR 60-89 min/min)
- GFR of 60 may represent 50% loss in function
- Parathyroid Hormone starts to increase
- Stage 3: Moderate reduction (GFR 30-59 ml/min)
- Calcium absorption decreases
- Malnutrition onset
- Anemia secondary to Erythropoietin deficiency
- Left Ventricular Hypertrophy
- Stage 4: Severe reduction (GFR 15-29 ml/min)
- Serum Triglycerides increase
- Hyperphosphatemia
- Metabolic Acidosis
- Hyperkalemia
- Stage 5: Kidney Failure (GFR <15 ml/min)
- Azotemia
- References
- (2002) Am J Kidney Dis 39:S1
- Snively (2004) Am Fam Physician 70:1921-30
- Labs: Screening for Chronic Kidney Disease
- Indications
- History or Family History of causes listed above
- All patients over age 60 years old
- Initial Screening Tests
- Serum Creatinine
- Urinalysis with microscopy
- Assess Glomerular Filtration Rate (GFR)
- Estimations generally as accurate as 24 hour urine
- See Creatinine Clearance for exceptions
- Formyla
- Cockcroft-Gault equation or
- Modification of Diet in Renal Disease (MDRD)
- Assess for Proteinuria
- General
- First morning void spot urine is preferred sample
- Step 1: Standard Urine Dipstick for screening
- Step 2a: Urine Dipstick 1+ or greater
- Obtain protein to Creatinine ratio
- Ratio > 200 mg protein/gram Creatinine
- Evaluate Proteinuria
- Ratio > 200 mg protein/gram Creatinine
- Repeat protein to Creatinine ratio yearly
- Step 2b: Urine Dipstick negative or trace
- Obtain microalbumin to Creatinine ratio
- Ratio > 30 mg microalbumin/gram Creatinine
- Evaluate Microalbuminuria
- Ratio < 30 mg microalbumin/gram Creatinine
- Repeat microalbumin to Creatinine ratio yearly
- Assess other urinary sediment on Urinalysis
- Lipiduria (seen in nephrotic sediment)
- Indicated by fatty casts, oval fat bodies, or free fat in urine sediment
- Increases significance of Proteinuria
- Hematuria
- Urine White Blood Cells
- Labs: Urine sediment found in causes of Chronic Kidney Disease
- Polycystic Kidney Disease
- Protein to Creatinine ratio 200-1000 mg/g
- Red Blood Cells present
- Diabetic Nephropathy
- Albumin to Creatinine ratio 30-300 early (and exceeds 300 in later disease)
- Hereditary Nephritis
- Protein to Creatinine ratio <1000 mg/g
- Red Blood Cells, tubular cells and granular casts present
- Hypertensive Nephropathy
- Protein to Creatinine ratio 200-1000 mg/g
- Noninflammatory Glomerular Disease
- Protein to Creatinine ratio >1000 mg/g
- Proliferative Glomerulonephritis
- Protein to Creatinine ratio >500 mg/g
- Red Blood Cells, Red Blood Cell casts, White Blood Cells, White Blood Cell casts present
- Tubulointerstitial Nephritis
- Protein to Creatinine ratio 200-1000 mg/g
- Red Blood Cells, White Blood Cells, White Blood Cell casts present
- Imaging: Renal Ultrasound (indicated in most patients on initial presentation)
- Doppler Ultrasound
- Renal veins: Venous thrombosis
- Renal arteries: Lower efficacy in diagnosing Renal Artery Stenosis
- General findings
- Nephrocalcinosis
- Hydronephrosis
- Renal Mass or complex cysts (concerning for malignancy risk)
- Renal stones
- Increased echogenicity
- Renal disease
- Enlarged Kidneys
- Renal tumors
- Infiltrating disease
- Nephrotic Syndrome related conditions
- Asymmetric Kidney size or scarred Kidneys
- Vascular disease
- Urologic disease
- Tubulointerstitial disease
- Small, hyperechoic Kidneys
- Chronic Kidney Disease
- Imaging: Other advanced imaging
- Consider CT or MRI of Kidneys and Liver
- Consider Voiding Cystourethrogram
- Labs: Findings in Chronic Kidney Disease Stages 3-4
- Anemia (Normochromic, Normocytic)
- Hematocrit decreases
- Serum Creatinine > 2-3
- Glomerular Filtration Rate <20-30
- Results from decreased Erythropoietin synthesis
- Azotemia
- Decreased Serum Protein
- Serum chemistry abnormalities
- Hyperkalemia or Hypokalemia
- Metabolic Acidosis
- Hypocalcemia
- Hyperphosphatemia
- Labs: Screening
- Indications
- Diabetes Mellitus
- Hypertension
- Age over 55 years old
- Tests (combined)
- Estimated Glomerular Filtration Rate and
- Urine Protein to Creatinine Ratio
- Labs: Initial presentation
- Basic labs
- Basic metabolic panel
- Serum Calcium
- Serum Phosphorus
- Complete Blood Count (CBC)
- Vitamin D
- Additional labs as indicated
- Antinuclear Antibody (ANA)
- Lupus nephritis
- Urine and Serum Protein Electrophoresis
- Multiple Myeloma
- Infectious Disease serologies
- HBsAg (Membranous Nephropathy, membranoproliferative nephritis)
- xHBC Antibody (Membranous Nephropathy, membranoproliferative nephritis)
- HIV Test (focal and segmental glomerulosclerosis)
- Antistreptolysin O Antibody (ASO Titer)
- Post-Streptococcal Glomerulonephritis
- Antineutrophil Cytoplasmic Antibody (ANCA)
- Wegener granulomatosis
- Microscopic Polyangiitis
- Pauci-immune Rapidly Progressive Glomerulonephritis
- Anti-Glomerular Basement Membrane Antibody (Anti-GBM Antibody)
- Goodpasture Syndrome (xGBM Antibody associated with rapid progression)
- Consider complement studies (C3, C4, CH50)
- Post-Streptococcal Glomerulonephritis
- Membranoproliferative Glomerulonephritis
- Lupus nephritis
- Cryoglobulinemia
- Cryoglubulin Test
- Cryoglobulinemia
- Eosinophiluria
- Tubulointerstitial Disease
- Labs: Monitoring
- See Also Chronic Kidney Disease related Bone Disease (Renal Osteodystrophy)
- Labs to repeat every 3-12 months
- Serum Creatinine
- Serum electrolytes
- Serum Calcium
- Serum Phosphorus
- Serum Albumin
- Intact Parathyroid Hormone (iPTH)
- Labs to repeat every 12 months
- Quantitative measurement of Proteinuria
- Complete Blood Count, TIBC, Ferritin
- Serum Alkaline Phosphatase
- Diagnostics: Renal Biopsy
- Indications
- Hematuria and low Creatinine Clearance or Proteinuria
- Nephrotic range Proteinuria
- Chronic Renal Failure with normal or large Kidneys
- Acute Renal Failure of unknown cause
- Contraindications
- Renal length <9 cm
- Severe Hypertension
- Multiple large renal cysts
- Uncorrected bleeding tendency
- Hydronephrosis
- Acute infection
- Management: Secondary Prevention
- Preventive strategies
- See Prevention of Kidney Disease Progression
- See Drug Dosing in Chronic Kidney Disease
- See Renal Osteodystrophy
- See Nephrotoxic Drugs
- See Intravenous Contrast Related Acute Renal Failure
- See Gadolinium-Associated Nephrogenic Systemic Fibrosis (Nephrogenic Fibrosing Dermopathy)
- Referral to nephrology indications
- Chronic Kidney Disease Stage 4 (GFR <30 ml/minute)
- Consider initial evaluation when GFR <60 ml/minute
- Chronic Kidney Disease with rapid progression
- Unexplained decrease in GFR >30% over 4 months
- Acute failure complicating Chronic Kidney Disease
- Unclear etiology for Renal Failure
- Renal biopsy
- Nephrotic sediment (e.g. lipiduria)
- RBC casts (indicates an urgent referral)
- Urine Eosinophils
- Refractory Hypertension despite at least 3 antihypertensives
- Significant Proteinuria
- 24 Hour Urine Protein > 1000 mg
- Protein to Creatinine ratio >500-1000 mg/g
- Albumin to Creatinine ratio >300 mg/g
- Acute Tubular Necrosis
- Significant comorbidity (e.g. cardiovascular disease)
- Complications of Chronic Kidney Disease
- Anemia of Chronic Kidney Disease
- Bone and mineral disorders of Chronic Kidney Disease
- Hyperkalemia (potassium >5.5 meq despite modification of therapy)
- Management: End Stage Renal Disease
- Hemodialysis or peritoneal Dialysis
- Absolute Dialysis Indications
- Uremic Symptoms
- Uremic Pericarditis
- Relative Dialysis Indications
- Hypervolemia
- Hyperkalemia or other electrolyte abnormalities
- Severe Metabolic Acidosis
- Creatinine Clearance <10 ml/min (<15 ml/min in Diabetes Mellitus)
- Renal transplantation
- Less rejection if transplant before Dialysis started
- Mange (2001) N Engl J Med 344:726-31
- Conservative management options
- Non-Dialysis with Hospice care
- Delayed Dialysis until Creatinine Clearance <5 ml/min (similar morbidity and mortality)
- Cooper (2010) N Engl J Med 363(7):609-19
- Management: Erythropoietin (EPO)
- Efficacy
- Initial studies showed benefit for Erythropoietin
- Renicki (1995) Am J Kidney Dis 25:548-54
- Recent studies show no benefit and higher risk of Cerebrovascular Accident
- Outcomes are the same with and without normalized Hemoglobin via erythropoetin
- Morbidity and patient sense of well-being is not improved on erythropoetin
- Pfeffer (2009) N Engl J Med 361
- Indications for Erythropoeitin
- Hemoglobin <9 mg/dl
- Adverse effects
- Increased risk of Cerebrovascular Accident
- Management: Symptomatic Management in ESRD
- Agitation
- Haloperidol 1 mg PO, IV or IM every 12 hours
- Anorexia
- Minimize Uremia with adequate Dialysis frequency
- Consider Major Depression, Gastroparesis, and Xerostomia
- Dronabinol 2.5 mg orally before meals
- Megestro 400 mg orally daily
- Prednisone 10 mg orally daily
- Dyspnea
- Regular Physical Activity to prevent deconditioning
- Fentanyl (Duragesic) 12.5 mg IV or SQ every two hours as needed for end-of-life
- Fatigue
- Treat Anemia if present
- Consider Depression Management with Fluoxetine 20 mg daily or Sertraline 50 mg daily
- Nausea and Vomiting
- Minimize Uremia with adequate Dialysis frequency
- Ondansetron 4 mg orally every 8 hours
- Metoclopramide (Reglan) 5 mg twice daily
- Haloperidol (Haloperidol) 0.5 mg orally every 8 hours
- Pruritus
- Minimize Uremia with adequate Dialysis frequency
- Phosphate binders
- Standar Dry Skin therapy (e.g. barrier creams)
- Ondansetron 4 mg orally every 8 hours
- Hydroxyzine (Atarax or Vistaril), 25 mg orally every 6 hours
- Naltrexone (Revia) 50 mg orally daily
- Phototherapy (UV-B Light)
- Insomnia
- See Sleep Hygiene
- Treat Restless Leg Syndrome
- Treat Obstructive Sleep Apnea
- Zolpidem 5 mg orally at bedtime
- Temazepam (Restoril) 15 mg orally at bedtime
- Management: Advanced Directives
- Cardiopulmonary Resuscitation (CPR)
- Survival in ESRD is only 8% at hospital discharge and 3% at six months
- Contrast with CPR in non-ESRD with survival of 12% at discharge and 9% at six months
- Discuss Do-Not-Reuscitate status at routine visits
- Hospice
- Criteria to qualify for Hospice services paid by Medicare in End Stage Renal Disease
- ESRD on no-Dialysis management or
- ESRD on Dialysis and other Hospice qualifying condition (e.g. cancer)
- Complications
- Cardiovascular Disorders
- Coronary Artery Disease (21% of ESRD cases)
- Peripheral Vascular Disease
- Cardiac arrhythmias
- Congestive Heart Failure
- Erectile Dysfunction
- Pericarditis
- Neurologic disorders
- Peripheral Neuropathy
- Restless Leg Syndrome
- Sleep Disorders
- Fluids, Electrolytes and Nutrition
- Metabolic Acidosis
- Muscle wasting and malnutrition
- Pseudogout
- Gastrointestinal disorders
- Chronic Constipation
- Gastritis
- Miscellaneous disorders
- Chronic Kidney Disease related Bone Disease (Renal Osteodystrophy)
- Amenorrhea
- Pruritus
- Course
- Progression of Chronic Kidney Disease (<55 mmHg) is predictable
- Glomerular Filtration Rate (GFR) decreases -4 ml/min per year if no intervention
- Intensive management may halt GFR decline
- See Prevention of Kidney Disease Progression
- Major causes of death in ESRD
- Myocardial Infarction
- Cerebrovascular Accident
- Prognosis
- Annual mortality of ESRD: 24%
- Five Year survival
- All ages: 38%
- Age over 65 years: 18%
- References
- Golder (2003) AAFP Board Review, Seattle
- (2002) Am J Kidney Dis 39:s1-266
- Baumgarten (2011) Am Fam Physician 84(10): 1138-48
- Hood (1996) Postgrad Med 100(5):163-75
- Snyder (2005) Am Fam Physician 72(9):1723-32
- (2007) Am J Kidney Dis 49(2 suppl 2):S12-S154
- O'Connor (2012) Am Fam Physician 85(7):705-10
- Rivera (2012) Am Fam Physician 86(8): 749-54